To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:294 Issue:1 Number:6 ISSN#:2564-2537
ACE Report #14991
Ace Report Cover Osteoarthritis

Platelet-Rich Plasma vs. Novel Cross-linked Hyaluronic Acid Injection for Early Knee Osteoarthritis

How to Cite

OrthoEvidence. Platelet-Rich Plasma vs. Novel Cross-linked Hyaluronic Acid Injection for Early Knee Osteoarthritis. ACE Report. 2022;294(1):6. Available from:

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Comparing the Efficacy of Intra-Articular Single Platelet-Rich Plasma(PRP) versus Novel Crosslinked Hyaluronic Acid for Early-Stage Knee Osteoarthritis: A Prospective, Double-Blind, Randomized Controlled Trial

Medicina (Kaunas). 2022 Aug 1;58(8): 1028.

Contributing Authors:
YC Wang CL Lee YJ Chen YC Tien SY Lin CH Chen PP Chou HT Huang

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


116 patients with early-stage knee osteoarthritis were randomized to receive a single intra-articular injection of a novel cross-linked hyaluronic acid (HA; n=58) or platelet-rich plasma (PRP; n=58). The outcome of interest was the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and associated sub-scores, measured at 1, 3 and 6 months follow-up. Results revealed similar scor...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.